scholarly journals Evaluation of Chemotherapy Response with Serum Squamous Cell Carcinoma Antigen Level in Cervical Cancer Patients: A Prospective Cohort Study

PLoS ONE ◽  
2013 ◽  
Vol 8 (1) ◽  
pp. e54969 ◽  
Author(s):  
Mingzhu Yin ◽  
Yan Hou ◽  
Tao Zhang ◽  
Changyi Cui ◽  
Xiaohua Zhou ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cohort Study ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Chemotherapy Response ◽  
Antigen Level ◽  
Squamous Cell Carcinoma Antigen

scholarly journals Pre-diagnosis consumption of preserved vegetables and prognosis of invasive oesophageal squamous cell carcinoma: a prospective cohort study in one high-risk area in China

2018 ◽  
Vol 46 (10) ◽  
pp. 4306-4314 ◽  
Author(s):  
Feng Shi ◽  
Fengcai Yan ◽  
Mulan Jin ◽  
Hong Chang ◽  
Quan Zhou ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cohort Study ◽  
Cell Carcinoma ◽  
Survival Time ◽  
Median Survival ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Median Survival Time ◽  
Vegetable Consumption ◽  
Oesophageal Squamous Cell Carcinoma

Objective To investigate the prognostic effect of pre-diagnosis preserved vegetable consumption on oesophageal squamous cell carcinoma (ESCC) in Yanting County, China. Methods This prospective cohort study enrolled consecutive patients with ESCC. The pre-diagnosis diet consumption data were collected using a food frequency questionnaire at baseline. Preserved vegetable consumption was categorized into two groups: < 1/week and ≥1/week. Kaplan–Meier survival curve analysis with a log-rank test and a Cox proportional hazard regression model analysis were undertaken to compare the two consumption groups. Results The study enrolled 185 patients (121 males and 64 females) with ESCC. Patients consuming preserved vegetables ≥1/week had a median survival time of 41 months, but patients consuming preserved vegetables <1/week did not achieve a median survival time. The adjusted hazard ratio (HR) for an intake of ≥1/week was 1.58 (95% confidence interval [CI] 1.01, 2.47). Among ‘ever smokers’, the HR increased to 2.04 (95% CI 1.10, 3.77) and among ‘ever alcohol drinkers’, the HR increased to 2.50 (95% CI 1.33, 4.73). Among ‘never smokers’ or ‘never alcohol drinkers’, no significant association was observed. Conclusion A high consumption of preserved vegetables was associated with a poorer prognosis among patients with ESCC.

Squamous Cell Carcinoma Antigen Isoforms in Serum from Cervical Cancer Patients

Tumor Biology ◽  
2006 ◽  
Vol 27 (3) ◽  
pp. 142-152 ◽  
Author(s):  
Eva R&ouml;ijer ◽  
Henk W.A. de Bruijn ◽  
Ulrika Dahl&eacute;n ◽  
Ka ten Hoor ◽  
Maria Lundin ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Squamous Cell ◽  
Squamous Cell Carcinoma Antigen

scholarly journals Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jessica Paken ◽  
Cyril D. Govender ◽  
Mershen Pillay ◽  
Birhanu T. Ayele ◽  
Vikash Sewram
Keyword(s):  
South Africa ◽  
Cervical Cancer ◽  
Hearing Loss ◽  
Cohort Study ◽  
Cancer Patients ◽  
Prospective Cohort Study ◽  
High Frequency ◽  
Prospective Cohort ◽  
Multidisciplinary Approach ◽  
Limited Resource

Abstract Background Cervical cancer, one of the most common cancers affecting females in South Africa, commonly requires a cisplatin-based-treatment regimen, which has been associated with ototoxic side effects. However, cisplatin-associated ototoxicity is largely under-reported in South Africa, despite its impact of hearing loss having serious overt ramifications on the quality of life of these patients. Hence, a prospective cohort study was undertaken to assess the audiological changes in female cervical cancer patients receiving cisplatin therapy. Objective To present details of the feasibility study and initial results on hearing patterns in cervical cancer patients receiving cisplatin chemotherapy. . Methods Fifty cervical cancer patients commencing with cisplatin chemotherapy underwent audiological assessments at a hospital in South Africa at various time intervals. Assessments included case history, otoscopic examination, immittance audiometry, pure tone audiometry (including high-frequency audiometry), speech audiometry, and distortion product otoacoustic emission testing. Data analysis involved the use of descriptive statistics and the Cochran-Armitage trend test for a linear trend in proportions. Results Fifty participants, aged between 32 and 79 years (Mean: 53 years; SD = 11.00), were recruited. Clinical findings revealed an incidence of 100% ototoxic hearing loss at the one-month post-treatment, i.e., 98%  after three cycles of cisplatin and 2%  at one-month post-chemotherapy. Sensorineural hearing loss and high-frequency tinnitus were most common. Deterioration in hearing thresholds was more evident in the extended high-frequency range, with the number of “no-responses,” from 11,200 Hz to 20,000 Hz, increasing with each successive audiological evaluation. This study further indicated that recruitment and follow-up of study participants within a limited resource setting are possible. However, cognizance must be given to a multidisciplinary approach and constant engagement with participants through regular contact either telephonically or via a short-message-system. Conclusion Exposure to cisplatin treatment contributed to hearing loss in females with cervical cancer, highlighting the need for ototoxicity monitoring during chemotherapy treatments. Furthermore, the results indicate that it is possible to conduct prospective cohort studies, using a multidisciplinary approach in limited-resource environments with appropriate planning and training strategies, as this study was able to achieve its aim successfully.

Sign in / Sign up

Export Citation Format

Share Document